Bnl-108277-2015-Ja
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Differentiation of Recombinant Myoblasts In
DIFFERENTIATION OF RECOMBINANT MYOBLASTS IN ALGINATE MICROCAPSULES By KELLY MACMILLAN BOWIE, B.Sc. A Thesis Submitted to the school of Graduate Studies in Partial Fulfillment ofthe Requirements for the Degree Master ofScience McMaster University 1997 © Copyright by Kelly MacMillan Bowie, June, 1997 MASTER OF SCIENCE MCMASTER UNIVERSITY 1997 Hamilton, Ontario TITLE: Differentiation of Recombinant Myoblasts in Alginate Microcapsules AUTHOR: Kelly MacMillan Bowie, B.Sc. (University of Western Ontario) SUPERVISOR: Dr. P.L. Chang EXAMINING COMMITTEE: Dr. M.A. Rudnicki Dr. C. Nurse NUMBER OF PAGES: xii,l75 11 ABSTRACT A cost effective approach to the delivery of therapeutic gene products in vivo is to immunoprotect genetically-engineered, universal, non-autologous cells in biocompatible microcapsules before implantation. Myoblasts may be an ideal cell type for encapsulation due to their inherent ability to differentiate into myotubes, thereby eliminating the problem of cell overgrowth within the capsular space. To evaluate the interaction between the differentiation program and the secretory activity of the myoblasts within the microcapsule environment, we transfected C2C 12 myoblasts to express human growth hormone and followed their expression of muscle differentiation markers, such as creatine phosphate kinase (CPK) protein and up-regulation of muscle-specific genes (ie. myosin light chains 2 & 1/3, Troponin I slow, Troponin T, myogenin and MyoD1). As the transfected myoblasts were induced to differentiate for up to two weeks, their myogenic index (i.e. the percentage of multinucleate myoblasts) increased from 0 to -50%. Concomitantly, up-regulation of differentiation marker RNA levels, and as much as a 23-fold increase in CPK activity, were observed. -
1/05661 1 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... - 12 May 2011 (12.05.2011) W 2 11/05661 1 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/00 (2006.0 1) C12Q 1/48 (2006.0 1) kind of national protection available): AE, AG, AL, AM, C12Q 1/42 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 10/054171 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 26 October 2010 (26.10.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/255,068 26 October 2009 (26.10.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, MYREXIS, INC. -
DNA–Protein Interactions DNA–Protein Interactions
MethodsMethods inin MolecularMolecular BiologyBiologyTM VOLUME 148 DNA–ProteinDNA–Protein InteractionsInteractions PrinciplesPrinciples andand ProtocolsProtocols SECOND EDITION EditedEdited byby TTomom MossMoss POLII TFIIH HUMANA PRESS M e t h o d s i n M o l e c u l a r B I O L O G Y TM John M. Walker, Series Editor 178.`Antibody Phage Display: Methods and Protocols, edited by 147. Affinity Chromatography: Methods and Protocols, edited by Philippa M. O’Brien and Robert Aitken, 2001 Pascal Bailon, George K. Ehrlich, Wen-Jian Fung, and 177. Two-Hybrid Systems: Methods and Protocols, edited by Paul Wolfgang Berthold, 2000 N. MacDonald, 2001 146. Mass Spectrometry of Proteins and Peptides, edited by John 176. Steroid Receptor Methods: Protocols and Assays, edited by R. Chapman, 2000 Benjamin A. Lieberman, 2001 145. Bacterial Toxins: Methods and Protocols, edited by Otto Holst, 175. Genomics Protocols, edited by Michael P. Starkey and 2000 Ramnath Elaswarapu, 2001 144. Calpain Methods and Protocols, edited by John S. Elce, 2000 174. Epstein-Barr Virus Protocols, edited by Joanna B. Wilson 143. Protein Structure Prediction: Methods and Protocols, and Gerhard H. W. May, 2001 edited by David Webster, 2000 173. Calcium-Binding Protein Protocols, Volume 2: Methods and 142. Transforming Growth Factor-Beta Protocols, edited by Philip Techniques, edited by Hans J. Vogel, 2001 H. Howe, 2000 172. Calcium-Binding Protein Protocols, Volume 1: Reviews and 141. Plant Hormone Protocols, edited by Gregory A. Tucker and Case Histories, edited by Hans J. Vogel, 2001 Jeremy A. Roberts, 2000 171. Proteoglycan Protocols, edited by Renato V. Iozzo, 2001 140. -
Open Iyer PR__Thesis.Pdf
The Pennsylvania State University The Graduate School Department of Biochemistry and Molecular Biology BIOCHEMICAL CHARACTERIZATION OF THE PROTEINS INVOLVED IN GLUCONACETOBACTER HANSENII CELLULOSE SYNTHESIS A Dissertation in Integrative Biosciences by Radhakrishnan Iyer Prashanti 2012 Radhakrishnan Iyer Prashanti Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy August 2012 The dissertation of Radhakrishnan Iyer Prashanti was reviewed and approved* by the following: Ming Tien Professor of Biochemistry and Molecular Biology Dissertation Advisor Chair of Committee B. Tracy Nixon Professor of Biochemistry and Molecular Biology Nicole R. Brown Associate Professor of Wood Chemistry Charles T. Anderson Assistant Professor of Biology Peter J Hudson Program Chair, Integrative Biosciences Director, The Huck Institutes of the Life Sciences * Signatures are on file in the Graduate School ii ABSTRACT Gluconacetobacter hansenii is a Gram-negative bacterium, considered as the model organism for studying the process of cellulose biogenesis. This is due to its unique ability to synthesize and secrete copious amounts of cellulose as an extracellular polysaccharide, in its growth medium. G. hansenii is therefore an ideal bacterium to study cellulose as a material as well as cellulose synthesis as a biological process. We have therefore employed this bacterium as our subject for our inquiry into the biochemistry of the process of cellulose synthesis. In this work, the main area of focus is towards understanding the bacterial cellulose synthesis and secretion complex, in terms of its component proteins, their structure, organization and their interactions. Two parallel approaches were used to understand and gain insights into the cellulose synthesis complex. One was to heterologously express and purify the proteins that are known to be involved in cellulose synthesis for structural studies or for generation of antibodies. -
Targeting Myelin Lipid Metabolism As a Potential Therapeutic Strategy in a Model of CMT1A Neuropathy
ARTICLE DOI: 10.1038/s41467-018-05420-0 OPEN Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy R. Fledrich 1,2,3, T. Abdelaal 1,4,5, L. Rasch1,4, V. Bansal6, V. Schütza1,3, B. Brügger7, C. Lüchtenborg7, T. Prukop1,4,8, J. Stenzel1,4, R.U. Rahman6, D. Hermes 1,4, D. Ewers 1,4, W. Möbius 1,9, T. Ruhwedel1, I. Katona 10, J. Weis10, D. Klein11, R. Martini11, W. Brück12, W.C. Müller3, S. Bonn 6,13, I. Bechmann2, K.A. Nave1, R.M. Stassart 1,3,12 & M.W. Sereda1,4 1234567890():,; In patients with Charcot–Marie–Tooth disease 1A (CMT1A), peripheral nerves display aberrant myelination during postnatal development, followed by slowly progressive demye- lination and axonal loss during adult life. Here, we show that myelinating Schwann cells in a rat model of CMT1A exhibit a developmental defect that includes reduced transcription of genes required for myelin lipid biosynthesis. Consequently, lipid incorporation into myelin is reduced, leading to an overall distorted stoichiometry of myelin proteins and lipids with ultrastructural changes of the myelin sheath. Substitution of phosphatidylcholine and phosphatidylethanolamine in the diet is sufficient to overcome the myelination deficit of affected Schwann cells in vivo. This treatment rescues the number of myelinated axons in the peripheral nerves of the CMT rats and leads to a marked amelioration of neuropathic symptoms. We propose that lipid supplementation is an easily translatable potential therapeutic approach in CMT1A and possibly other dysmyelinating neuropathies. 1 Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Göttingen 37075, Germany. -
The Organization and Evolution of Biological Networks in Bacteria
The Organization and Evolution of Biological Networks in Bacteria Elucidating Biological Pathways and Complexes Involved in Bacterial Survival and Environmental Adaptation by Cedoljub Bundalovic-Torma A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Biochemistry University of Toronto © Copyright by Cedoljub Bundalovic-Torma 2018 ii The Organization and Evolution of Biological Networks in Bacteria: Systematic Exploration of Large-Scale Biological Networks in E. coli and Exopolysaccharide Biosynthetic Machineries. Cedoljub Bundalovic-Torma Doctor of Philosophy Department of Biochemistry University of Toronto 2018 Abstract Bacteria inhabit diverse environmental niches and employ various functional repertoires encoded in their genomes relevant for survival and adaptation. It has long been proposed that gene duplication plays an important role in bacterial adaptation, however systematic experimental study of the functional roles of duplicates in bacteria has been lacking. From decades of small- scale experimental work with the model bacterium, Escherichia coli, our view of the bacterial cell has expanded to encompass the concept of biological networks, a wiring diagram of the cell representing diverse functional associations of genes. To help define these complex functional relationships, large-scale genetic and protein interaction screens have been devised and applied to E. coli, providing datasets for deriving novel and biologically meaningful associations. In this work I present a study of gene duplication in the context of several large-scale biological networks. First (Chapter 2) I investigate two recently published E. coli genetic interaction (GI) networks, and find that duplicates are likely to contribute to increased robustness through epistatic buffering or integration in the context of biological pathways and protein complexes with broad biological roles1 and DNA damage and repair response pathways2. -
Molecular Basis for AU-Rich Element Recognition and Dimerization by the Hur C-Terminal RRM
Molecular basis for AU-rich element recognition and dimerization by the HuR C-terminal RRM Nina Ripina,b,1, Julien Boudeta, Malgorzata M. Duszczyka, Alexandra Hinnigerb, Michael Fallerb, Miroslav Kreplc,d, e e c,d b,1,2 a,1 Abhilash Gadi , Robert J. Schneider ,Jirí Sponer , Nicole C. Meisner-Kober , and Frédéric H.-T. Allain aDepartment of Biology, Institute of Molecular Biology and Biophysics, ETH Zürich, 8093 Zürich, Switzerland; bNovartis Institutes for BioMedical Research, 4002 Basel, Switzerland; cInstitute of Biophysics, Czech Academy of Sciences, 612 65 Brno, Czech Republic; dDepartment of Physical Chemistry, Faculty of Science, Regional Centre of Advanced Technologies and Materials, Palacky University Olomouc, 771 46 Olomouc, Czech Republic; and eDepartment of Microbiology, New York University School of Medicine, New York, NY 10016 Edited by Leemor Joshua-Tor, HHMI and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, and approved December 26, 2018 (received for review May 22, 2018) Human antigen R (HuR) is a key regulator of cellular mRNAs age during apoptosis (14). Mice lacking HuR show higher rates containing adenylate/uridylate–rich elements (AU-rich elements; of embryonic lethality (15). Conditional HuR knockout animals AREs). These are a major class of cis elements within 3′ untranslated revealed the essential role of HuR in organ development and regions, targeting these mRNAs for rapid degradation. HuR contains tissue homeostasis (16). Elevated HuR expression levels are as- three RNA recognition motifs (RRMs): a tandem RRM1 and 2, followed sociated with altered physiological functions, such as promoting by a flexible linker and a C-terminal RRM3. While RRM1 and 2 are viral infections, neurological pathologies, and muscular disorders. -
Ep 1 117 822 B1
Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 117 822 B1 (12) EUROPÄISCHE PATENTSCHRIFT (45) Veröffentlichungstag und Bekanntmachung des (51) Int Cl.: Hinweises auf die Patenterteilung: C12P 19/18 (2006.01) C12N 9/10 (2006.01) 03.05.2006 Patentblatt 2006/18 C12N 15/54 (2006.01) C08B 30/00 (2006.01) A61K 47/36 (2006.01) (21) Anmeldenummer: 99950660.3 (86) Internationale Anmeldenummer: (22) Anmeldetag: 07.10.1999 PCT/EP1999/007518 (87) Internationale Veröffentlichungsnummer: WO 2000/022155 (20.04.2000 Gazette 2000/16) (54) HERSTELLUNG VON POLYGLUCANEN DURCH AMYLOSUCRASE IN GEGENWART EINER TRANSFERASE PREPARATION OF POLYGLUCANS BY AMYLOSUCRASE IN THE PRESENCE OF A TRANSFERASE PREPARATION DES POLYGLUCANES PAR AMYLOSUCRASE EN PRESENCE D’UNE TRANSFERASE (84) Benannte Vertragsstaaten: (56) Entgegenhaltungen: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU WO-A-00/14249 WO-A-00/22140 MC NL PT SE WO-A-95/31553 (30) Priorität: 09.10.1998 DE 19846492 • OKADA, GENTARO ET AL: "New studies on amylosucrase, a bacterial.alpha.-D-glucosylase (43) Veröffentlichungstag der Anmeldung: that directly converts sucrose to a glycogen- 25.07.2001 Patentblatt 2001/30 like.alpha.-glucan" J. BIOL. CHEM. (1974), 249(1), 126-35, XP000867741 (73) Patentinhaber: Südzucker AG Mannheim/ • BUTTCHER, VOLKER ET AL: "Cloning and Ochsenfurt characterization of the gene for amylosucrase 68165 Mannheim (DE) from Neisseria polysaccharea: production of a linear.alpha.-1,4-glucan" J. BACTERIOL. (1997), (72) Erfinder: 179(10), 3324-3330, XP002129879 • GALLERT, Karl-Christian • DE MONTALK, G. POTOCKI ET AL: "Sequence D-61184 Karben (DE) analysis of the gene encoding amylosucrase • BENGS, Holger from Neisseria polysaccharea and D-60598 Frankfurt am Main (DE) characterization of the recombinant enzyme" J. -
O O2 Enzymes Available from Sigma Enzymes Available from Sigma
COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc. -
Revealing Higher Order Protein Structure Using Mass Spectrometry
B American Society for Mass Spectrometry, 2016 J. Am. Soc. Mass Spectrom. (2016) DOI: 10.1007/s13361-016-1385-1 FOCUS: MASS SPECTROMETRY AS A PROBE OF HIGHER ORDER PROTEIN STRUCTURE: ACCOUNT & PERSPECTIVE Revealing Higher Order Protein Structure Using Mass Spectrometry Brian T. Chait,1 Martine Cadene,2 Paul Dominic Olinares,1 Michael P. Rout,3 Yi Shi1 1Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY 10065, USA 2CBM, CNRS UPR4301, Rue Charles Sadron, CS 80054, 45071, Orleans Cedex 2, France 3Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065, USA Abstract. The development of rapid, sensitive, and accurate mass spectrometric methods for measuring peptides, proteins, and even intact protein assemblies has made mass spectrometry (MS) an extraordinarily enabling tool for structural biology. Here, we provide a personal perspective of the increasingly useful role that mass spectrometric techniques are exerting during the elucidationofhigherorderproteinstructures.Areas covered in this brief perspective include MS as an enabling tool for the high resolution structural biologist, for compositional analysis of endogenous protein complexes, for stoichiometry determination, as well as for integrated approaches for the structural elucidation of protein complexes. We conclude with a vision for the future role of MS- based techniques in the development of a multi-scale molecular microscope. Keywords: Mass spectrometry, Higher order structure, Structural biology, -
12) United States Patent (10
US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S. -
Bcsa and Bcsb Form the Catalytically Active Core of Bacterial Cellulose Synthase Sufficient for in Vitro Cellulose Synthesis
BcsA and BcsB form the catalytically active core of bacterial cellulose synthase sufficient for in vitro cellulose synthesis Okako Omadjelaa, Adishesh Naraharia, Joanna Strumillob, Hugo Mélidac, Olga Mazurd, Vincent Bulonec, and Jochen Zimmera,1 aCenter for Membrane Biology, Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908; bFaculty of Biology and Environmental Protection, University of Lodz, 90-231 Lodz, Poland; cDivision of Glycoscience, School of Biotechnology, Royal Institute of Technology, AlbaNova University Center, 106 91 Stockholm, Sweden; and dDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216 Edited by Chris R. Somerville, University of California, Berkeley, CA, and approved September 20, 2013 (received for review July 24, 2013) Cellulose is a linear extracellular polysaccharide. It is synthesized reaction, and the membrane-embedded part forms a TM pore in by membrane-embedded glycosyltransferases that processively close juxtaposition with the catalytic site, thereby allowing trans- polymerize UDP-activated glucose. Polymer synthesis is coupled to location of the nascent polysaccharide (2). membrane translocation through a channel formed by the cellu- Although most eukaryotic CesAs are believed to form supra- lose synthase. Although eukaryotic cellulose synthases function in molecular complexes that organize the secreted glucans into macromolecular complexes containing several different enzyme cable-like structures,